These are the 5 articles most viewed this year…so here is a recap for your to dive back in and read what you missed.
5 Reasons Big-Company Execs are Defecting to Biotech
The biotechnology sector remains a long-term outperform relative to other indices. Liftstream analysed five reasons for the industry’s big-executive-names to dive into a world of start-up. The key words are capital flows, innovation, collaboration, entrepreneurship and rewards.
Boston’s Biotech Women Take Center Stage
Five women executives’ recent awards, appointments to the board of directors and funding deals in the Boston Biotech Cluster.
Biotech Investors Follow Pattern in Funding and Hiring Executives
Biotechnology ventures show patterns in investing and hiring. A disproportionate amount of capital is allocated to companies with all-male boards. Women are under-represented in venture funded companies, either among the leadership or the board directors.
Board Succession Requires Refreshing Plan
Succession planning requires improving board diversity, making sure that a board or executive replacement process is comprehensive in the search for diverse candidates. The recent focus has been on the poor level of gender diversity at the board level among both private and public companies.
European Biotech Begins to Show Big Ambition
European biotech companies are deepening their financial resources to achieve growth. Oxford-based Immunocore banked a $320m investment round to supports its effort of building a premier biotech company based on ImmTAC technology platform.
